Aliskiren and valsartan combination therapy for the management of hypertension.
about
Rationale for nebivolol/valsartan combination for hypertension: review of preclinical and clinical data.Aliskiren for the treatment of essential hypertension under real-life practice conditions: design and baseline data of the prospective 3A registry.Evaluation and pharmacologic approach to patients with resistant hypertension.Anti-stress and nootropic activity of drugs affecting the renin-angiotensin system in rats based on indirect biochemical evidence.Two-Year Outcomes of Patients Treated With Aliskiren Under Clinical Practice Conditions: Non-Interventional Prospective Study.
P2860
Aliskiren and valsartan combination therapy for the management of hypertension.
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Aliskiren and valsartan combination therapy for the management of hypertension.
@ast
Aliskiren and valsartan combination therapy for the management of hypertension.
@en
Aliskiren and valsartan combination therapy for the management of hypertension.
@nl
type
label
Aliskiren and valsartan combination therapy for the management of hypertension.
@ast
Aliskiren and valsartan combination therapy for the management of hypertension.
@en
Aliskiren and valsartan combination therapy for the management of hypertension.
@nl
prefLabel
Aliskiren and valsartan combination therapy for the management of hypertension.
@ast
Aliskiren and valsartan combination therapy for the management of hypertension.
@en
Aliskiren and valsartan combination therapy for the management of hypertension.
@nl
P2860
P921
P356
P1476
Aliskiren and valsartan combination therapy for the management of hypertension.
@en
P2093
Benjamin J Epstein
P2860
P304
P356
10.2147/VHRM.S8175
P407
P577
2010-09-07T00:00:00Z